Safety of Anti-hepatitis B Virus Therapy During Pregnancy and Lactation

Dongli SUN,Caihong ZHENG

DOI: https://doi.org/10.13748/j.cnki.issn1007-7693.2017.11.029

2017-01-01

Abstract:Hepatitis B virus (HBV) infection is a worldwide epidemic,while the mother-to-child transmission is the main route of transmission of HBV infection in China.Women of childbearing age often faced with antiviral therapy problem during pregnancy and lactation.Through the retrieval of domestic and foreign database literature,all the approved drugs for anti-hepatitis B virus infection (including interferon α,lamivudine,telbivudine,tenofovir dipivoxil,entecavir,adefovir dipivoxil And enquitril) in pregnancy and lactation using safety data and experience were summarized,and presented by placental transport,animal reproductive toxicity and teratogenicity studies,experience of using in human pregnancy,drug milk secretion and experience of using in human lactation.Among them,research data of tenofovir and telbivudine is relatively sufficient and can be used as a choice of anti-HBV treatment during pregnancy.No teratogenic of both is found in animal studies,and the incidence of birth defects is not increased while tenofovir and telbivudine were employed in human pregnancy.Lamivudine is widely used during pregnancy in human (HIV treatment),and no increase in the incidence of birth defects,it may also be used as one of the options for anti-HBV treatment during pregnancy.